ITEM 1.01ENTRY INTO A DEFINITIVE MATERIAL AGREEMENT
On
Under the terms of the MOU, the Company and Giostar will jointly partner together for a COVID-19 Investigational New Drug ("IND") to the FDA using the Company's umbilical cord mesenchymal stem cell product AlloRx Stem Cells™ in a clinical trial to treat Covid-19 patients.
ITEM 7.01REGULATION FD DISCLOSURE
On
The information in this Current Report on Form 8-K furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section, and they shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. By filing this Current Report on Form 8-K and furnishing this information pursuant to Item 7.01, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.
ITEM 9.01:EXHIBITS Item Title 10.1 Memorandum of Understanding 99.1 Press Release
© Edgar Online, source